Logo der Universität Basel

Research Database / FORSCHUNGSDATENBANK 
PRINTDOC
 
Publication 1195706 | Verified
 

Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1195706
Author(s) Colleoni, Marco; Giobbie-Hurder, Anita; Regan, Meredith M; Thürlimann, Beat; Mouridsen, Henning; Mauriac, Louis; Forbes, John F; Paridaens, Robert; Láng, István; Smith, Ian; Chirgwin, Jacquie; Pienkowski, Tadeusz; Wardley, Andrew; Price, Karen N; Gelber, Richard D; Coates, Alan S; Goldhirsch, Aron
Author(s) at UniBasel Thürlimann, Beat
Year 2011
Title Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Journal Journal of clinical oncology
Volume 29
Number 9
Pages / Article-Number 1117-24
Abstract Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR). We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy.
Publisher American Society of Clinical Oncology
ISSN/ISBN 0732-183X
edoc-URL http://edoc.unibas.ch/dok/A6005887
Full Text on edoc No
Digital Object Identifier DOI 10.1200/JCO.2010.31.6455
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/21321298
ISI-Number WOS:000288532500023
Document type (ISI) Journal Article, Randomized Controlled Trial
 
   

MCSS v5.8 PRO. 0.354 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
03/05/2024